Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-FLAG Induction Therapy in Poor Prognosis AML, MDS and Relapsed/Refractory ALL
NCT00003619Phase 2Completed
- Sponsor
- Drexel University
- Start
- Feb 1998
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of topotecan in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Drexel University. Primary endpoints: Safety and Toxicity and Maximum Tolerated Dose. Started Feb 1998; status: completed.
02
Drugs
topotecan
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00003619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003619.